2020 American Transplant Congress
A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus
*Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…2020 American Transplant Congress
Late Intra-Patient Tacrolimus Variability Predicts De Novo Donor-Specific Antibody and Graft Loss
*Purpose: Intra-patient variability (IPV) of tacrolimus level has been associated with poor outcomes after kidney transplantation. However, these findings were limited mainly to measurements early…2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…2020 American Transplant Congress
Safety and Efficacy of Valganciclovir for Cytomegalovirus Prophylaxis in Solid Organ Transplant Patients on Hemodialysis
Houston Methodist Hospital, Houston, TX
*Purpose: Cytomegalovirus (CMV) is the most common viral infection after solid organ transplant (SOT) and is associated with significant morbidity and mortality. Valganciclovir (VGCV) is…2019 American Transplant Congress
Time to First Therapeutic Tacrolimus Trough in Kidney Transplant Recipients: A Comparison of a Weight Based versus a Non-Weight Based Dosing Strategy
Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Reaching a therapeutic tacrolimus (TAC) trough early post-kidney transplant is important in minimizing the risk of acute rejection. The aim of this study was…2019 American Transplant Congress
CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing
*Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »